 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ST316 / Sapience Therap
ST316, a peptide antagonist of ?-Catenin, depletes immunosuppressive myeloid cell populations and enhances anti-cancer immune responses in in vivo tumor models and in patients (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1219;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- ST316 / Sapience Therap
ST316, a clinical peptide antagonist of beta-catenin, induces anti-tumor immune responses by multiple mechanisms of action (Section 4) - Mar 5, 2024 - Abstract #AACR2024AACR_8304;
P1
Second, ST316 induced CD155/PVR upregulation and T-cell activation in the presence of anti-TIGIT antibody. Collectively these results suggest a novel immune-modulatory role for ST316 in the TIME and provide rational for combination therapy with checkpoint inhibitors.
- ST316 / Sapience Therap
Anti-tumor and immunostimulatory properties of ST316, a peptide antagonist of beta-catenin for treatment of cancers with aberrant Wnt pathway activity. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_468;
- ||| ST316 / Sapience Therap
Enrollment open, Metastases: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (clinicaltrials.gov) - Jun 22, 2023
P1, N=156, Recruiting, Sponsor: Sapience Therapeutics
Collectively these results suggest a novel immune-modulatory role for ST316 in the TIME and provide rational for combination therapy with checkpoint inhibitors. Not yet recruiting --> Recruiting
- ||| ST316 / Sapience Therap
New P1 trial, Metastases: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (clinicaltrials.gov) - May 8, 2023
P1, N=156, Not yet recruiting, Sponsor: Sapience Therapeutics
- ST316 / Sapience Therap
Immunotherapeutic potential of ST316, a peptide antagonist of ?-catenin (Section 35; Poster Board #8) - Mar 14, 2023 - Abstract #AACR2023AACR_2073;
Anti-tumor activity was accompanied by an increase the M1/M2 ratio. Overall, these results support the immuno-therapeutic potential of ST316 and extend the application range of ST316 to include Wnt-driven cancers with poor clinical response to immune checkpoint blockade and other immunotherapeutic agents.
- ST316 / Sapience Therap
β-catenin antagonist peptide, ST316, attenuates Wnt-dependent oncogenic activity (Section 16) - Mar 9, 2022 - Abstract #AACR2022AACR_2367;
ST316 (5 mg/kg) administered three times weekly by subcutaneous injection resulted in 99.6% tumor growth inhibition vs. vehicle controls (p<0.05), while a negative control peptide had no significant impact on tumor growth. These data demonstrate the potential of ST316 as a potent therapeutic candidate for Wnt/β-catenin-dependent cancers.